NCT05472558View on ClinicalTrials.gov

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
B-cell Non Hodgkin Lymphoma
Interventions
BIOLOGICAL

anti-CD19 CAR-NK

lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER